Last reviewed · How we verify

NCT02904252

The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital

Completed Last updated 23 March 2017
What this trial tests

trial testing Transient elastography in Hepatitis C in 158 participants. Completed in 31 October 2016.

Timeline
1 January 2016
Primary endpoint
31 October 2016
31 October 2016

Quick facts

Lead sponsorMahidol University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment158
Start date1 January 2016
Primary completion31 October 2016
Estimated completion31 October 2016
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Mahidol University

Who can join

18 and older, any sex, with Hepatitis C or Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to assess the prevalence and genotypes of HCV infection in thalassemia major and thalassemia intermediate patients who have received blood transfusion in the Department of Medicine, Faculty of Medicine Siriraj Hospital. The secondary objective is to identify the effect of HCV infection as well as the risk factors of advanced liver disease and liver cirrhosis in these patients The third objective is to identify the role of serum HA level and fibrotest in the prediction of cirrhosis in these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Transient elastography

Trials testing the same drug.

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

Other Mahidol University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02904252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing